These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 11574925

  • 1. Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpesvirus-associated immune restoration disease after start of highly active antiretroviral therapy.
    Stone SF, Price P, Brochier J, French MA.
    J Infect Dis; 2001 Oct 15; 184(8):1073-7. PubMed ID: 11574925
    [Abstract] [Full Text] [Related]

  • 2. Effect of highly active anti-retroviral therapy and hepatitis C virus co-infection on serum levels of pro-inflammatory and immunoregulatory cytokines in human immunodeficiency virus-1-infected individuals.
    Tornero C, Alberola J, Tamarit A, Navarro D.
    Clin Microbiol Infect; 2006 Jun 15; 12(6):555-60. PubMed ID: 16700705
    [Abstract] [Full Text] [Related]

  • 3. Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment.
    Stone SF, Price P, Tay-Kearney ML, French MA.
    J Infect Dis; 2002 Jun 15; 185(12):1813-7. PubMed ID: 12085331
    [Abstract] [Full Text] [Related]

  • 4. Immune restoration disease in HIV patients: aberrant immune responses after antiretroviral therapy.
    French M, Price P.
    J HIV Ther; 2002 May 15; 7(2):46-51. PubMed ID: 12553688
    [Abstract] [Full Text] [Related]

  • 5. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy.
    Ostrowski SR, Katzenstein TL, Pedersen M, Høyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H.
    Scand J Immunol; 2006 Jun 15; 63(6):478-86. PubMed ID: 16764702
    [Abstract] [Full Text] [Related]

  • 6. Varicella zoster as a manifestation of immune restoration disease in HIV-infected children.
    Tangsinmankong N, Kamchaisatian W, Lujan-Zilbermann J, Brown CL, Sleasman JW, Emmanuel PJ.
    J Allergy Clin Immunol; 2004 Apr 15; 113(4):742-6. PubMed ID: 15100682
    [Abstract] [Full Text] [Related]

  • 7. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD, HepaI.Co.N.A. Study Group, Italian Cohort Naive for Antiretrovirals Study Group.
    Clin Infect Dis; 2005 Jun 15; 40(12):e101-9. PubMed ID: 15909251
    [Abstract] [Full Text] [Related]

  • 8. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients.
    Stone SF, Lee S, Keane NM, Price P, French MA.
    J Infect Dis; 2002 Nov 15; 186(10):1498-502. PubMed ID: 12404169
    [Abstract] [Full Text] [Related]

  • 9. Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART.
    Stone SF, Price P, Keane NM, Murray RJ, French MA.
    HIV Med; 2002 Jan 15; 3(1):21-7. PubMed ID: 12059947
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antiretroviral therapy. Immune restoration disease in HIV-infected patients on HAART.
    French MA.
    AIDS Read; 1999 Nov 15; 9(8):548-9, 554-5, 559-62. PubMed ID: 11082733
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Immune restoration disease in HIV-infected individuals receiving highly active antiretroviral therapy: clinical and immunological characteristics.
    de Boer MG, Kroon FP, Kauffmann RH, Vriesendorp R, Zwinderman K, van Dissel JT.
    Neth J Med; 2003 Dec 15; 61(12):408-12. PubMed ID: 15025416
    [Abstract] [Full Text] [Related]

  • 17. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.
    Phillips P, Bonner S, Gataric N, Bai T, Wilcox P, Hogg R, O'Shaughnessy M, Montaner J.
    Clin Infect Dis; 2005 Nov 15; 41(10):1483-97. PubMed ID: 16231262
    [Abstract] [Full Text] [Related]

  • 18. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution.
    Safdar A, Rubocki RJ, Horvath JA, Narayan KK, Waldron RL.
    Clin Infect Dis; 2002 Nov 15; 35(10):1250-7. PubMed ID: 12410486
    [Abstract] [Full Text] [Related]

  • 19. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, Erice A, Bucy RP, Kilby JM, Lederman MM, Hamilton CD, Lertora J, White BL, Tebas P, Duliege AM, Pollard RB, AIDS Clinical Trials Group 328 Study Team.
    Arch Intern Med; 2007 Mar 26; 167(6):597-605. PubMed ID: 17389292
    [Abstract] [Full Text] [Related]

  • 20. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL.
    APMIS Suppl; 2003 Mar 26; (114):1-37. PubMed ID: 14626050
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.